Endocrinologia, diabetes y nutricion · 2018
Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update.
СтатьяКлинические рекомендацииНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gomez-Peralta Fernando, Escalada San Martín Francisco Javier, Menéndez Torre Edelmiro, Mata Cases Manel, Ferrer García Juan Carlos, Ezkurra Loiola Patxi, Ávila Lachica Luis, Fornos Pérez Jose Antonio, Artola Menéndez Sara, Álvarez-Guisasola Fernando, Rica Echevarría Itxaso, Girbés Borrás Juan, en representación del Grupo de Trabajo de Consensos y Guías Clínicas
Аннотация
Type 2 diabetes mellitus (DM2) has become a problem of global dimensions by their high and growing prevalence worldwide and the personal and economic costs associated with it. Correct treatment can reduce mortality and associated complications. New concepts have recently been included in routine clinical practice and have changed the algorithm of DM2 pharmacological therapy. Therefore, the Spanish Society of Diabetes (SED) entrusted to the Working Group of Consensus and Clinical Guidelines an update of the 2010 document Recommendations for Pharmacological Treatment of Hyperglycemia in Diabetes type2. Novel aspects include nine characteristics to describe each drug group: efficiency, the risk of hypoglycemia, effects on body weight, the demonstrated effect in cardiovascular risk, nephroprotection, limitation of use in renal insufficiency, the rate of secondary effects, complexity and costs. Additionally, the document details combination options, and develop the start and adjustment of available injectable therapies.